Sirolimus

Generic Name: Sirolimus

Brand Names: Fyarro, Hyftor, Rapamune

Drug Type: Small Molecule

Chemical Formula: C_₅₁H_₇₉NO_₁₃

CAS Number: 53123-88-9

Unique Ingredient Identifier: W36ZG6FT64

Background: Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...

Indication: Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...

Associated Conditions: Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms

Associated Therapies: -

Clinical Trials

Initial in vivo validation of novel cancer therapeutics using AI

Oxford Drug Design's AI platform, SynthAI, validated in vivo with a 28-day mouse trial showing efficacy and dose response against MCF7 breast cancer cells. The platform's precision aims to deliver more efficacious and safer cancer treatments, accelerating development and reducing costs. The company plans to advance these treatments into clinical trials.

avma.org

3 months ago

New listings in AVMA Veterinary Clinical Trials Registry – September 2024

The AVMA’s Veterinary Clinical Trials Registry connects clinical scientists with veterinarians and owners for animal health studies. It features improved browsing, sharing, and study submission processes. Recent studies include treatments for oral cancer in cats, canine hemangiosarcoma, osteosarcoma in dogs, and more.

nature.com

3 months ago

In vivo CAR T cells move into clinical trials

Gene therapy tools enabling in vivo CAR T generation offer potential to make CAR T therapies faster, better, and cheaper, bypassing ex vivo limitations. Companies like Interius and Umoja are pioneering this approach with engineered lentiviral vectors and lipid nanoparticles, targeting immune cells directly in the body. This shift could blur the lines between cell and gene therapies, with initial trials in cancer and autoimmune diseases expected to yield significant insights by 2026.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy